Abstract
Tertiary lymphoid structures (TLSs) are useful biomarkers for predicting the prognosis and assessing the response to immunotherapy in many cancers. In Merkel cell carcinoma (MCC), however, TLSs have only been examined in MCPyV-positive cases and were reported not to correlate with the prognosis. Here, we examined the prognostic value of TLSs in 61 patients with MCC, including both MCPyV-positive and MCPyV-negative cases. TLS-positive samples had a significantly better prognosis than TLS-negative samples.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
